Epstein-Barr virus-induced, posttransplant lymphoproliferative disorders

被引：381

作者：

Paya, CV ^{[1
]}

Fung, JJ

Nalesnik, MA

Kieff, E

Green, M

Gores, G

Habermann, TM

Wiesner, RH

Swinnen, LJ

Woodle, ES

Bromberg, JS

机构：

[1] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA

[3] Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA

[4] Mayo Clin, Mayo Transplant Ctr, Rochester, MN 55905 USA

[5] Univ Pittsburgh, Dept Transplantat Surg, Pittsburgh, PA 15260 USA

[6] Univ Pittsburgh, Div Transplantat, Pittsburgh, PA 15260 USA

[7] Harvard Univ, Dept Med, Boston, MA 02115 USA

[8] Harvard Univ, Dept Microbiol & Mol Genet, Boston, MA 02115 USA

[9] Childrens Hosp Pittsburgh, Div Allergy Immunol & Infect Dis, Pittsburgh, PA 15213 USA

[10] Mayo Clin, Div Gastroenterol, Rochester, MN 55905 USA

[11] Mayo Clin, Mayo Transplant Ctr, Rochester, MN 55905 USA

[12] Mayo Clin, Div Hematol, Rochester, MI USA

[13] Loyola Univ, Med Ctr, Div Hematol Oncol, Maywood, IL 60153 USA

[14] Univ Chicago, Dept Surg, Chicago, IL 60637 USA

[15] Univ Michigan, Ctr Med, Dept Surg, Ann Arbor, MI 48109 USA

[16] Univ Michigan, Ctr Med, Div Transplantat, Ann Arbor, MI 48109 USA

来源：

TRANSPLANTATION | 1999年 / 68卷 / 10期

关键词：

D O I：

10.1097/00007890-199911270-00015

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.

引用

页码：1517 / 1525

页数：9

共 71 条

[1]

Abedi MR, 1997, INT J CANCER, V71, P624, DOI 10.1002/(SICI)1097-0215(19970516)71:4<624::AID-IJC19>3.0.CO

[2]

2-B

[3]

ANDERSSON J, 1985, SCAND J INFECT DIS, P107

[4] Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome [J].